Ocular Immunology and Inflammation· 2026Q2
Real-World Safety and Effectiveness of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis: A Post-Marketing Surveillance Study in Korea
- 0citations
- Q2SCImago
- 2026year
Short summary
Adalimumab treatment in Korean patients with non-infectious intermediate, posterior, or panuveitis (NIIPPU) showed an acceptable safety profile and potential effectiveness, with a significant decrease in corticosteroid use and improvement in inflammation markers.
AI-generated from the title and abstract; the full text is not read.
Key points
- Adalimumab treatment in 155 Korean NIIPPU patients showed a 1.9% rate of serious adverse events and no serious adverse drug reactions.
- The mean daily corticosteroid dose decreased significantly from 9.7 mg to 6.6 mg during the study.
- Anterior chamber inflammation and vitreous haze improved significantly from baseline to 22 weeks.
- Best corrected visual acuity (BCVA) did not worsen in patients treated with adalimumab.
- Cost was the most common reason for discontinuation (64.7%) among 34 patients.
AI-generated from the title and abstract; the full text is not read.
Abstract
Purpose This post-marketing surveillance study reports the real-world safety and effectiveness of adalimumab (Humira®, AbbVie Inc.) among patients with non-infectious intermediate, posterior, or panuveitis (NIIPPU) in Korea.Methods The study was conducted at 17 medical centres from January 2018 to July 2020. Safety (155 patients) was analysed by collecting adverse events (AEs) and adverse drug reactions (ADRs) data. Effectiveness assessments (148 patients) included anterior chamber cell grade, vitreous haze grade, and best corrected visual acuity (BCVA) change.Results At baseline, the mean duration of uveitis was 3.9 ± 4.0 years (n = 101) and the mean number of relapses in the past year was 2.5 (n = 52). The most common anatomical uveitis phenotype was panuveitis (n = 110, 71.0%). One patient received prior infliximab; within the previous 3 months, 75.4% and 93.3% of patients received glucocorticoids and immunosuppressants, respectively. The mean daily corticosteroid dose decreased from 9.7 ± 7.8 mg at the start of the study to 6.6 ± 6.0 mg at the end of the study (p < 0.0001). AEs and ADRs were reported in 13 patients (8.4%, 1.9% serious) and 5 patients (3.2%), respectively. The most common ADR was injection-site discomfort. Twenty-nine patients (18.7%) discontinued adalimumab within 6 months; 34 patients discontinued during follow-up, most commonly for cost issues (64.7%). Three patients discontinued adalimumab due to AEs. Regarding effectiveness, from baseline to 22 weeks, anterior chamber inflammation and vitreous haze tended to improve significantly; there was no BCVA worsening.Conclusion In the real-world setting, adalimumab treatment showed an acceptable safety profile, with serious AEs reported in three patients but no serious ADRs related to adalimumab, and demonstrated potential effectiveness in Korean patients with NIIPPU.
The authors' abstract, as published at the source. Ocular Immunology and Inflammation, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Immunology and Allergy
Immunology and AllergyMedicine